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Neoplastic lymphocytes from 3 patients with wide-
spread cutaneous T cell lymphoma were karyotyped, 
using a chromosome banding technique. None of the 
patients had previously received chemotherapy. Mor-
phologically homogeneous populations of abnormal T 
cells were available from 2 distinct body regions of 2 of 
the individuals and from the bone marrow of the third. 
Karyotypes from each of the 3 patients indicated mono-
clonality of their lymphoma. These observations suggest 
that extracutaneous dissemination of cutaneous T cell 
lymphoma involves spread of neoplastic cells derived 
from a single clone. If future studies can demonstrate 
that those neoplastic T cells actually localized in the skin 
are also progeny of a single malignant cell, a widely 
accepted co~cept that . cutaneous T cell lymphoma is of 
multifocal origin will have to be reexamined. 
The obsevation that those lymphomas involving broad ex-
panses of skin are regularly neoplasms of cells with membrane 
properties characteristic of T cells has led to the broad desig-
nation of this group as "cutaneous T cell lymphoma" [1,2]. The 
validity of this classification is further supported by reports 
that the malignant cells of the Sezary syndrome [3], mycosis 
fungoides and other variants of cutaneous T cell lymphoma 
(CTCL) frequently have in vitro functional capabilities of 
"helper" T cells [4] and by documentation of transitions be-
tween different histologic and clinical expressions of CTCL in 
individual patients [3]. 
We provide evidence in this paper that 3 examples of extra-
cutaneous dissemination of CTCL occur via seeding of distinct 
body regions by cells of monoclonal derivation. These obser-
vations have caused us to reconsider the concept that CTCL 
begins as a multifocal process in the skin, the premise upon 
which currently accepted clinical staging systems of this type 
of lymphoma have been based. 
METHODS 
Patients 
Three patients (TC # 2519544, , EO # 2393707, EM # 2442776), with 
presenting complaints of widespread skin disease, offered special op-
portunities to study the chromosomal characteristics in cutaneous T 
cell lymphoma. In addition to widespread cutaneous infIltration, 2 of 
the 3 patients had at least 2 distinct body regions from which large 
numbers of neoplastic cells could be recovered. The other patient was 
leukemic with extensive bone marrow involvement. None had received 
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systemic chemotherapy prior to study. Pertinent aspects of their case 
histories are concisely reported below, and the membrane properties 
and functional capabilities of the neoplastic T cells are reported in 
greater detail separately [5]. 
A written, informed consent in compliance with the Columbia Col-
lege of Physicians & Surgeons Human Investigation Committee was 
signed by each patient prior to study. 
TC, a 43-yr-old male, presented with papules and nodules covering 
most of his trunk and extremities. Histologically, these lesions were 
characterized by intense perivascular infIltration of the papillary and 
reticular dermis and subcutis by atypical mononuclear cells. The over-
lying epidermis was not infiltrated. Generalized lymphadenopathy was 
present, and examination of an excised lymph node revealed diffuse 
infIltration by cells morphologically similar to those in the skin. Eighty-
three percent of the cells obtained from that lymph node formed E 
rosettes with neuraminidase-treated sheep erythrocytes (E) by the 
method of Weiner, Bianco, and Nussenzweig [6] and 14% formed 
rosettes with E secondarily coated with IgM anti-Forssman antibody 
and murine complement (EAC) as previously described [7]. On biopsy, 
bone marrow was focally involved by the lymphomatous process, but 
the peripheral blood counts were remarkable only for an absolute 
lymphopenia of 1500-1800/id. Because of the widespread skin involve-
ment and demonstration of T cell membrane features on most cells 
infiltrating the lymph node, the patient was considered to have cuta-
neous T cell lymphoma, histologically and clinically unclassifiable as 
mycosis fugoides or the Sezary syndrome. 
EO, a 50-yr-old female, had generalized cutaneous plaques and 
tumors, with histology characteristic of mycosis fungo ides, including 
Pautrier microabscesses in the epidermis [1]. In addition, she had two 
large subcutaneous tumors, on her left th igh and left shoulder, measur-
ing 4 and 6 cm in diameter, respectively. The former lesion was totally 
excised, and a major portion of t.he latter was removed. Microscopically, 
both consisted of homogeneous sheets of large atypical mononuclear 
cells with irregular nuclei and with nucleoli. Fifty-six percent of the 
cells obtained from the thigh lesion formed E rosettes, while 3% formed 
EAC rosettes. Thirty-nine percent of the cells obtained from the 
shoulder lesion formed E rosettes, and zero percent formed EAC 
rosettes. A lymph node was also markedly. involved, with complete 
effacement of normal architecture. She was considered to have ad-
vanced mycosis fungo ides. 
EM; a 60-yr-old female, a patient with generalized erythroderma, 
was in blast crisis with a blood leukocyte count of 174,000/1'1. More 
than 95% of these cells had deeply folded nuclei characteristic of Sezary 
cells by light microscopy [8,9], and 94% of her blood mononuclear cells 
formed E rosettes, while only 1% formed EAC rosettes. Her bone 
marrow was essentially replaced by these atypical cells. Because of the 
morphology of the atypical circulating leukocytes, the erythroderma 
and cutaneous histology characterized by a dense upper dermal infil-
trate consisting of atypical mononuclear cells, her disease was consid-
ered to be a clinically aggressive example of the Sezary syndrome 
[10]. 
Karyotype Analysis 
Cells were obtained from bone marrow or lymph nodes removed for 
diagnostic purposes. Bone marrow specimens were examined directly 
or were cultured for 24 hr in RPMI 1640 supplemented with 15% fetal 
calf serum (Gibco, Grand Island, N.Y) prior to karyotyping. 
Portions of the excised lymph nodes or tumor were fine ly minced 
with scalpels in Hanks buffered salt solution and passed through 40 11m 
sieves to obtain cell suspension. Karyotypes were studied from direct 
lymph node preparations or from cell suspensions cultured for 3 days 
with doses of mitogens predetermined to optimally induce mitosis (40 
I'g/ml of concanavalin, 5 I'g/m1 of phytohemagglutinin or 5 I'g/ml of 
pokeweed). Direct preparations were chromosome banded using quin-
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acrine staining and examined under ultraviolet microscopy [ll]. Slides 
Were also prepared from 3-day cultures of mononuclear leukocytes with 
mitogens from the solid tissue sources and chromosome banding of 
metaphases was performed using a trypsin-Giemsa technique [12]. The 
nomenclature used to describe the karyotypes was that established by 
the Paris Conference [13]. 
RESULTS AND DISCUSSION 
As summarized in the Table, karyotype analysis was per-
formed on cells from each of the 3 patients with CTCL. In each 
case, identifiable structural alterations were noted. 
A ll abnormal karyotypes seen in preparations from TC's bone 
marrow and lymph node contained a translocation between 
chromosomes 4 and 14 and revealed absence of a chromosome 
16. In addition, trisomy of chromosome 14 and an additional X 
chromosome with a short arm deletion were evident in cells 
from the lymph node (Table and Figure) . 
S imilarly, cells from preparations of both tumors from EO 
had remarkably consistent karyotypes (Table) . Deletion of the 
long arm of chromosome 1 at band q 42, an extra chromosome 
3, the same 2 marker chromosomes (Ml, M2) and loss of one 
chromosome 11 and 12 were found in all abnormal cells. Several 
other marker chromosomes were seen in cells from the left 
shoulder tumor. No normal mitotic figures were identified in 
either cell population. 
Preparations of bone marrow from EM also contained abnor· 
mal mitotic figures. Each of 20 examined cells had identical 
translocations between chromosome 2 and 9 and between chro-
mosomes 2 and 13, as well as similar markers involving chro-
mosomes 17 and 19. No normal karyotypes were seen. 
In summary, remarkably consistent chromosome structural 
changes and karyotypes were ident ified in abnormal cells from 
each individual patient, indicating monoclonality of the malig-
nancy. In essence, these banding studies reveal "chromosomal 
fingerprints" distinctive for neoplastic cells of each individual 
patient. The multiple structural changes identified in these 
karyotypes constitute the strongest evidence for monoclonality 
that current technology can provide. However, no single aber-
ration was characteristic of the 3 individuals as a group. 
Previous failures to identify clonal chromosomal changes in 
cutaneous T cell lymphoma may have resulted from prior 
treatment of the patients with agents known to cause chromo-
some breaks and rearrangements from studying patients with 
more longstanding disease and subclone formation or from lack 
of banding studies [14-19]. Also, ' it is frequently difficult to 
ind uce in vitro mitosis [20] in the abnormal cells of chronic T 
cell neoplasms, and the more effective response to mitogens by 
normal T cells often obscures the residual neoplastic cells. The 
availability from our 3 patients oflarge homogeneous masses of 
neoplastic cells not previously exposed to antimitotic agents 
obviated the above problems. 
Most significantly, our observations suggest that CTCL (in-
cluding mycosis fungoides and the Sezary syndrome) is, in at 
least advanced disease, a monoclonal process. These findings 
s u ggest, but do not prove, that CTCL may be monoclonal at 
inception. Alternatively, the disease may initially be polyconal 
with ultimate evolution of and overgrowth by a single particu-
larly aggressive clone. 
The possibility that cutaneous T cell lymphoma may be 
monoclonal at onset challenges the validity of suggested staging 
systems for this variety of neoplasm [21,22] in which it is 
considered common for widespread involvement of noncontig-
uous skin regions to occur prior to involvement of extracuta-
neous t issues and on which the rationale of topical treatment 
or radiotherapy of skin is based. Such staging systems are based 
on the concept that CTCL begins multifocally in the skin. 
Al though neoplastic cells of CTCL exhibit a remarkable affinity 
for the skin, our finding of monoclonal origin of cells present in 
distinct body areas indicates hematogenous spread with seeding 
of secondary sites. These observations do not preclude the 
possibility that the disease is initially multifocal with secondary 
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Karyotypes from lymph node (A) and bone marrow (B). from TC. 
Translocation between chromosomes 4 and 14 and absence of a chro· 
mosome 16 are seen in both preparations (arrows). 
Chromosome analysis 
Type of Preparation Chromosome Patient Tissue No. cells examined Karyotype Markers" Mitogen No. 
Te Bone marrow Culture None 4 Abnormal 44 / 45 -16, t(4;14) 
20 Normal 46 normal 
Lymph node Direct None Phythohem- 4 Abnormal/O normal 47 -16, t(4; 14) + Xp-,+ 14 
culture agglutinin 4 Normal/ O abnormal 46 normal 
EO Tumor left thigh Culture Pokeweed 7 Abnormal 46 +3, -11, -12, lq- , M
" 
M 2 
Tumor left shoulder Culture Pokeweed 10 Abnormal 47-48 + 3, - 11, -12, lq-, M" Mz, 
o Normal M ",-M,; 
E M Bone marrow Culture 20 Abnormal 46 -21, -22, t(2;9), t(2;13), 
o Normal l7p+,19p+ 
" t denotes translocation between chromosomes in parenthesis; + refers to extra chromosomal material; - refers to deletion of chromosomal 
material; p represents short arm of designated chromosome; and q represents long arm of designated chromosome. 
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consistent chromosome "fingerprints" found in malignant cells 
from individual patients clearly indicates monoclonality of the 
process at the time of study. It must be emphasized that for 
practical reasons the present study was limited to the exami-
nation of extracutaneous sites of involvement by CTCL. If 
future studies demonstrate similar monoclonality of the neo-
plastic T cells actually in cutaneous lesions, clinicians must 
consider the possibility that systemic spread of the process has 
occurred by the time involvement of noncontiguous areas of 
skin can be identified. Systemic therapy would naturally then 
be required. Although defmitive evidence that CTCL is mono-
clonal even at time of origin is not presently available, the 
frequently observed failure of treatment limited to the skin in 
the clinical setting of disseminated cutaneous lesions [21- 24] 
and reports that widespread dissemination of lymphoma with 
primary manifestations in the skin is a common occurrence [23] 
underscore the possibility that CTCL may be disseminated to 
extracutaneous sites earlier than generally appreciated. 
The authors are grateful to Ms. Barbara Peabody for her assistance 
in the preparation of this manuscript. 
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